Latest news and press releases about Genenta Science S.p.A. (GNTA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter.
Price
| Price | $0.74 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | IT |
Valuation Ratios
| Price / Book | 0.64 |
| EV / EBITDA | -3.14 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -36.82% |
| Return on Invested Capital | -21.33% |
| Return on Assets | -19.60% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BRNS · CVM · INMB · IPSC · JUNS · MDCX · MRSN
Explore sector: Healthcare · Biotechnology
More sections of GNTA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks